HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
| H.C. Wainwright 27th Annual Global Investment Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | 1x1 Investor Meetings Only |
| Morgan Stanley 23rd Annual Global Healthcare Conference | |
| Date: | Wednesday, September 10, 2025 |
| Format: | Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings |
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$26.62 |
| Daily Change: | -0.38 -1.41 |
| Daily Volume: | 3,077 |
| Market Cap: | US$104.880M |
November 06, 2025 September 02, 2025 August 12, 2025 August 07, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
